Clinical trials: Algorithms
Upper Airway Obstruction, Respiratory Insufficiency
Astral VAPS AutoEPAP Clinical Trial
Patients with chronic respiratory failure such as those associated with Chronic Obstructive Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS), Obstructive Sleep Apnea (OSA) or Neuromuscular Disease (NMD) are…
- Conditions
- Upper Airway Obstruction, Respiratory Insufficiency, Respiratory Failure
- Trial name
- NCT02683772
- Testing
- Astral
- Where
- 5 sites in United States
- Volunteers
- 42 people
- Sponsor
- ResMed
Sinus Node Disease, AV Block
Ingenio Device Algorithm Study
The purpose of the IVORY Study is to gather data to support global submissions/approvals for some models of the Ingenio device family.
- Conditions
- Sinus Node Disease, AV Block, Heart Failure
- Trial name
- IVORY (NCT01441583)
- Testing
- RAAT, RYTHMIQ
- Where
- 21 sites in Austria, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Boston Scientific Corporation
Diabetes, Diabetes Mellitus, Type 2
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
This trial is conducted in Europe, North America and the United States of America. The aim of this trial is to compare two different titration algorithms of insulin degludec/liraglutide.
- Trial name
- DUAL™ VI (NCT02298192)
- Testing
- insulin degludec/liraglutide
- Where
- 84 sites in United States, Austria and 7 more
- Volunteers
- 420 people
- Sponsor
- Novo Nordisk A/S
Depression, Anxiety
Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Antidepressants are among the most widely prescribed medications, yet only 35-45% of patients achieve remission following an initial antidepressant trial.
- Trial name
- UHS (NCT01632267)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Assurex Health Inc.
Atrial Fibrillation, Persistent
FLOW-AF: A Study to Evaluate Electrographic Flow™ (EGF) Mapping Technology
This study is to evaluate Electrographic Flow™ (EGF) mapping algorithm technology (Ablamap® Software).
- Trial name
- FLOW-AF (NCT04473963)
- Testing
- Electrographic Flow™ guided ablation
- Where
- 4 sites in Czechia, Germany and 1 more
- Volunteers
- 85 people
- Sponsor
- Cortex
Chronic Kidney Disease (CKD)
A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis
A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.
- Trial name
- NCT02504294
- Testing
- Epoetin Hospira Arm, Standard of Care Arm, IV Iron
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 432 people
- Sponsor
- Pfizer
Malignant Melanoma
Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes
The main purpose of this study was to evaluate the impact on pyrexia-related outcomes of an adapted pyrexia adverse event (AE)-management algorithm, as well as safety, efficacy and health-related outcomes.
- Trial name
- COMBI-APlus (NCT03551626)
- Testing
- Dabrafenib, Trametinib
- Where
- 100 sites in Argentina, Australia and 21 more
- Volunteers
- 552 people
- Sponsor
- Novartis Pharmaceuticals
Hearing Loss
Evaluation of Nucleus 6 Sound Coding Algorithms
The purpose of the study was to evaluate the features of the Nucleus 6 Sound Processor (CP900 series) on existing Nucleus recipients who currently use the previous generation sound processor, the Cochlear Nucleus CP810 (also…
- Trial name
- NCT01854879
- Testing
- Nucleus 6 sound processor
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Cochlear
Urinary Incontinence
Collection of Real-life Measurement Data for TENA SmartCare Change Indicator in Subjects With Urinary Incontinence
This study is an explorative, open, single-arm clinical investigation to collect real-life measurement data in order to assess the mathematical algorithms involved in TENA SmartCare Change Indicator.
- Trial name
- NCT04071301
- Testing
- TENA SmartCare Change Indicator
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Essity Hygiene and Health AB
Heart Failure
Chronotropic Incompetence (CI) Diagnostic Algorithm in Heart Failure Patients
This study is to collect human activity and electrocardiogram (ECG) data from heart failure (HF) patients to aid in the development of a novel chronotropic incompetence (CI) algorithm designed to diagnose CI in patients with HF.
- Trial name
- NCT02358603
- Testing
- Chronotropic Incompetence Diagnostic Algorithm
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Cardiovascular Diseases
Management of Device Detected AT and Impact of Device Treatment Algorithms on Atrial Fibrillation
The MANDATE-AF study was designed to address evidence needs in India for device-based management of AF using AT/AF (Atrial Tachycardia/Atrial fibrillation) diagnostic features and therapies such as Reactive Atrial anti…
- Trial name
- MANDATE-AF (NCT04172883)
- Testing
- Treatment arm
- Where
- 11 sites in India
- Volunteers
- 79 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
Atrial Fibrillation Algorithms Clinical Validation Study
The purpose of the study is to evaluate the performances of investigational Irregular Rhythm Notification Feature (version 2.0) and Atrial Fibrillation History Feature algorithms.
- Trial name
- NCT04699812
- Testing
- ELECTROCARDIOGRAM (ECG) PATCH WEAR
- Where
- 4 sites in United States
- Volunteers
- 573 people, healthy volunteers welcome
- Sponsor
- Apple Inc.
Schizophrenia, Schizoaffective Disorders
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
The goal of this study is to answer the following questions: Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine Whether taking amantadine…
- Trial name
- NCT00401973
- Testing
- olanzapine, amantadine, metformin
- Where
- 15 sites in United States, Brazil and 5 more
- Volunteers
- 199 people
- Sponsor
- Eli Lilly and Company
Myopia, Astigmatism
New Treatment Algorithm to Reduce Spherical Aberration After LASIK Correction for Myopia
The purpose of this clinical trial is to demonstrate that treatments generated by an investigational algorithm reduces spherical aberration compared to currently available iDesign treatments.
- Trial name
- NCT01988415
- Testing
- VSS-Rx1 OPM vs Commercial iDesign Treatment
- Where
- Colombia
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Abbott Medical Optics
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine
This trial is conducted in Africa, Asia, Europe and the United States of America (USA). The aim of the trial is to compare the efficacy and safety of two different titration algorithms for insulin degludec/insulin aspart…
- Trial name
- BOOST® (NCT01680341)
- Testing
- insulin degludec/insulin aspart
- Where
- 45 sites in United States, Algeria and 3 more
- Volunteers
- 272 people
- Sponsor
- Novo Nordisk A/S
Heart Failure
Evaluation of Automatic Threshold Algorithms
This study will evaluate the PaceSafe Right Ventricular Autothreshold (RVAT) and Left Ventricular Autothreshold (LVAT) features for AUTOGEN Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices.
- Trial name
- CAPTIVATE (NCT02097290)
- Testing
- CRT-D
- Where
- 36 sites in United States
- Volunteers
- 216 people
- Sponsor
- Boston Scientific Corporation
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Respiratory Insufficiency, Obesity Hypoventilation Syndrome
Juno Perth Clinical Trial
This study is to evaluate the efficacy of a new therapy (Automatic Expiratory Positive Airway Pressure with intelligent Volume Assured Pressure Support (AutoEPAP iVAPS)) designed to treat respiratory insufficiency, respiratory…
- Conditions
- Respiratory Insufficiency, Obesity Hypoventilation Syndrome, Chronic Obstructive Pulmonary Disease (COPD), Neuromuscular Disease
- Trial name
- NCT02317042
- Testing
- Juno
- Where
- 2 sites in Australia
- Volunteers
- 25 people
- Sponsor
- ResMed
Diabetes Mellitus, Diabetes Mellitus, Type 1
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm
The purpose of this multi-center, prospective clinical study is to evaluate the performance of a novel, implanted Senseonics continuous glucose monitoring system (Senseonics CGM System) compared to Yellow Springs Instrument (YSI)…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PRECISION (NCT03251079)
- Testing
- Continuous glucose monitoring system
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Senseonics, Inc.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens
This trial is conducted in Asia and North America. The aim of this trial is to compare the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily in insulin-naïve subjects with type 2 diabetes mellitus when…
- Trial name
- BOOST™ (NCT01365507)
- Testing
- insulin degludec/insulin aspart
- Where
- 42 sites in United States, Malaysia and 5 more
- Volunteers
- 276 people
- Sponsor
- Novo Nordisk A/S